Effect of temperature reduction on responsiveness to cholinomimetics in the taenia caeci of the guinea-pig.
1. The effect of temperature reduction on the interaction of carbachol (CCh) and McN-A-343 (McN) with muscarinic receptors in the guinea-pig taenia caeci was investigated. 2. McN, a partial agonist, acted on the smooth muscle to produce contraction. The response was unaffected by tetrodotoxin and the pKB for inhibition by pirenzepine was 6.8, indicating that ganglionic M1 receptors were not involved in the response. 3. Reduction in temperature from 37 degrees C to 18 degrees C for 3 h led to a marked reduction in the contractile response to McN (2-200 microM) but no reduction in the response to CCh (0.1-3 microM). 4. The reduction in temperature was not accompanied by any change in the affinity of McN or CCh for muscarine receptors in binding experiments with [3H]-QNB. 5. The KA value for CCh determined after irreversible receptor inactivation with propylbenzilylcholine mustard followed by ca 60-min wash-out was 7.6 microM, a value similar to that obtained in binding experiments. 6. The EC50 for McN in producing contraction at 37 degrees C (2.1 microM) was similar to the KA value for the partial agonist obtained in experiments with the irreversible antagonist phenoxybenzamine (2.5 microM). It was also similar to the KB value determined at 18 degrees C (3.4 microM) when McN could be used as an antagonist of contractions to CCh. 7. At 18 degrees C, phosphatidylinositol (PI) hydrolysis by CCh was reduced to 23% of that at 37 degrees C. 8. It is concluded that reduction of muscarinic receptor activation of the PI pathway by cholinomimetics with lowering of the temperature could account for the findings with McN on contractility.
Darroch
S A
SA
School of Pharmacology, Victorian College of Pharmacy, Parkville, Australia.
Gardner
A
A
Vong
Y M
YM
Choo
L K
LK
Mitchelson
F
F
D008455:(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002217:Carbachol / Q000494:pharmacology; D003106:Colon / Q000187:drug effects*; D004347:Drug Interactions; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007295:Inositol Phosphates / Q000378:metabolism; D007700:Kinetics; D009119:Muscle Contraction / Q000187:drug effects; D010277:Parasympathomimetics / Q000494:pharmacology*; D010643:Phenoxybenzamine / Q000494:pharmacology; D010890:Pirenzepine / Q000494:pharmacology; D011438:Propylbenzilylcholine Mustard / Q000494:pharmacology; D011813:Quinuclidinyl Benzilate / Q000378:metabolism; D013696:Temperature
D007295:Inositol Phosphates; D010277:Parasympathomimetics; D010643:Phenoxybenzamine; D011438:Propylbenzilylcholine Mustard; D010890:Pirenzepine; D008455:(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride; D011813:Quinuclidinyl Benzilate; D001285:Atropine; D002217:Carbachol